Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy starts working from your very first injection, but most people notice meaningful appetite changes somewhere between weeks two and eight, and measurable weight loss typically becomes visible around weeks four to twelve. The honest answer is that the timeline varies — because the starting dose of 0.25mg is designed to help your body adjust, not to suppress appetite at full force from day one. These are prescription-only medicines that require clinical assessment before you can start; a prescriber decides whether Wegovy is right for you and which dose schedule suits your circumstances.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen you inject contains 0.25mg of semaglutide. That dose exists for one reason: to let your digestive system settle in, not to produce rapid weight loss. Nausea, bloating and changes in appetite are common early on, and the gradual starting schedule is specifically designed to reduce how disruptive those effects are. So if you finish your first month and feel like not much has happened, that is broadly expected.
What is changing, even if you cannot feel it yet, is how your gut and brain are beginning to communicate. Semaglutide activates GLP-1 receptors that are involved in signalling fullness and slowing how quickly food moves through your stomach. Those signals build over time rather than switching on at full intensity immediately.
A practical habit worth building in week one: weigh yourself on the same morning, before eating, and write it down. One single number, once a week, is enough. It removes the noise of daily fluctuation and gives you a genuine baseline to compare against as the weeks progress. The Wegovy treatment overview has more on how the dose schedule unfolds.
For many people, the first noticeable change is not on the scales, it is at the dinner table. Portions feel like enough sooner. The pull towards snacking in the evening loosens a little. If you are curious about when Wegovy starts working, this appetite shift often arrives somewhere between weeks two and six, and it is usually the first real signal that the medicine is active.
Weight loss on the scales tends to follow. Based on the STEP 1 trial data, published in the New England Journal of Medicine, participants at the 2.4mg maintenance dose lost an average of around 15% of their body weight over 68 weeks. The weight did not fall away in the first month; it accumulated steadily as the dose increased and appetite remained reduced over time.
In practice, the period between roughly weeks four and twelve is when most people taking Wegovy first report visible progress. That coincides with moving through the 0.5mg and 1mg dose steps. There is more on this progression at when Wegovy starts working for weight loss, including why the early weeks sometimes feel slower than expected.
No. And understanding why is more useful than comparing yourself to someone else's week-eight photo. Starting weight matters: someone with a higher body weight may see a larger absolute drop on the scales early on, while the percentage shift is what tends to equalise over time. Metabolic rate, sleep, physical activity and dietary habits all interact with how the medicine works.
There is also the question of how your body tolerates the titration. Some people move through the dose steps without much difficulty; others need more time at a lower dose before increasing. Slowing the titration is a clinical decision, it does not mean the medicine is failing.
The NHS's guidance on semaglutide for patients covers what to expect at each stage and what side effects to watch for, and it is worth reading alongside whatever your prescriber tells you. If you are weighing up how Wegovy compares to other options, whether Wegovy really works looks at the broader evidence base.
First: slow early progress is not the same as no progress. The first four months of Wegovy treatment are largely about titration and tolerance, and the clinical trials measured outcomes at 68 weeks, not eight. If you want a clearer picture of when you really start losing weight on Wegovy, expecting dramatic results before you reach your maintenance dose sets an unrealistic bar.
That said, some people do respond less strongly than others. NICE guidance notes that if less than 5% weight loss is achieved after six months on the maintenance dose, continuing treatment is reviewed. That is a clinical conversation, not something to navigate alone.
If you are worried your response is genuinely slower than it should be, the right step is to speak to your prescriber rather than increase your dose independently or consider buying from an unverified source. There is some context on what treatment costs include and why the source matters at Wegovy pricing in the UK, worth reading if you are feeling the pressure to cut corners. For broader questions about treatment options, our weight-loss treatment overview explains what is available and how to get started. And if you have questions our FAQs do not cover, our support team is available seven days a week.
When you feel ready to take the next step, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not an automated system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.